SCHEMBL4873644

SCHEMBL4873644

Fc1cc(F)c(-c2cnn3ccccc23)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNK O75909 1/20 0.46
CDK12 Q9NYV4 1/20 0.46
DYRK1A Q13627 1/20 0.43
EPHB3 P54753 3/20 0.43
ACVR1 Q04771 2/20 0.41
CAMKK1 Q8N5S9 1/20 0.40
CAMKK2 Q96RR4 1/20 0.40
JAK2 O60674 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DRD3 P35462 3/20 0.36
DRD4 P21917 2/20 0.36
PIK3CD O00329 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21631058 0.79 DYRK1A (0.46) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL22995014 0.76 EPHB3 (0.50) CCNKCDK12DYRK1AEPHB3KDM4E
SCHEMBL18160954 0.73 CAMKK1 (0.50) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL3467001 0.71 DYRK1A (0.55) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL16796062 0.70 DYRK1A (0.54) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL8045820 0.70 CCNK (0.41) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL2348287 0.70 DYRK1A (0.44) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL3313922 0.70 DYRK1A (0.47) CCNKCDK12DYRK1AEPHB3ACVR1
SCHEMBL16795290 0.70 DYRK1A (0.47) CCNKCDK12DYRK1AEPHB3JAK2
SCHEMBL16795169 0.70 DYRK1A (0.47) CCNKCDK12DYRK1AEPHB3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365066-B2 Pyrazolopyridine derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-04-29 US disclosed
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents BEIGHT DOUGLAS W 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents TGFB2, TGFB1, TGFBR1 CCNK 1383/4885CDK12 1670/4885DYRK1A 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.